This weekly vaccines update covers early-stage clinical progress, immunotherapy research, manufacturing expansion initiatives, and new safety and efficacy data reviews.
In Today’s Newsletter
Dive deeper
🦠 US Army advances hantavirus vaccine research [1] [US • 8 May 2026]
https://www.dongascience.com/en/news/77798
Context: Researchers cited neutralizing antibody generation as a potential effectiveness marker because hantavirus outbreaks are geographically dispersed and rare.
Key point: USAMRIID reported completed Phase 1 clinical trials for DNA vaccines targeting Andes, Hantaan, and Puumala hantavirus strains.
Implication: May influence prescriber choice and payer reviews pending full data.
🧠 Personalized glioblastoma vaccine shows early promise [2] [US • 12 May 2026]
https://medicine.washu.edu/news/personalized-vaccine-shows-promise-against-aggressive-brain-cancer/
Context: The vaccine targeted up to 40 neoantigens per patient; one participant remained recurrence-free nearly five years after diagnosis.
Key point: Personalized DNA vaccine GNOS-PV01 generated immune responses in most participants and showed encouraging recurrence-free and overall survival trends in a nine-patient Phase 1 glioblastoma study.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Evaxion previews AML vaccine data at EHA 2026 [3] [EU • 12 May 2026]
https://evaxion.ai/?press_release_id=11176
Context: EVX-04 targets endogenous retroviral antigens identified using the company’s AI-Immunology™ platform; a clinical trial application is planned for H2 2026.
Key point: Evaxion announced upcoming presentation of preclinical characterization data for EVX-04, an AI-designed off-the-shelf AML therapeutic vaccine.
Implication: Signals pipeline investment and modality expansion.
🤰 Large Tdap pregnancy review supports infant protection [4] [13 May 2026]
https://www.contemporaryobgyn.net/view/comprehensive-review-of-tdap-vaccine-during-pregnancy-confirms-infant-protection-maternal-safety
Context: The review incorporated more than 14,000 papers and included 62 newer studies published between 2020 and Mar 2026.
Key point: Systematic review and meta-analysis across 91 studies found maternal Tdap vaccination reduced infant pertussis risk while maintaining a consistent safety profile.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🫁 Ab&B Bio-Tech starts RSV vaccine Phase I/II program [5] [China • 14 May 2026]
https://www.minichart.com.sg/2026/05/14/abb-bio-tech-announces-phase-i-ii-clinical-trials-for-high-yield-recombinant-rsv-vaccine-cho-cell-and-highlights-superior-preclinical-results/
Context: Preclinical studies reported higher expression yields, improved thermal stability, and stronger neutralizing antibody responses versus referenced marketed products.
Key point: Ab&B Bio-Tech initiated Phase I/II testing of its recombinant RSV vaccine candidate using CHO-cell expression technology.
Implication: May influence prescriber choice and payer reviews pending full data.
🌍 IFC expands financing for Biovac manufacturing project [6] [Africa • 12 May 2026]
https://businessreport.co.za/companies/2026-05-12-ifc-secures-additional-private-capital-for-biovac-vaccine-manufacturing-project-in-africa/
Context: The package included $20 million from Proparco and $20 million from private sector credit insurers, increasing IFC-linked debt investment to $40 million.
Key point: IFC secured additional private capital for Biovac’s Kilimanjaro vaccine manufacturing project in South Africa.
Implication: Access programs may expand screening, initiation, and follow-up at scale.
Why it matters
- Personalized cancer vaccines continue moving from concept-stage immunotherapy toward early clinical validation in difficult-to-treat tumors such as glioblastoma. [2]
- Hantavirus preparedness remains limited by the absence of licensed vaccines despite high reported fatality rates for some strains. [1]
- AI-enabled antigen discovery platforms are increasingly being applied to hematologic cancers and off-the-shelf vaccine design. [3]
- Maternal immunization remains a central strategy for protecting infants before routine vaccination schedules begin. [4]
- Regional vaccine manufacturing initiatives in Africa and China reflect broader efforts to improve supply-chain resilience and local production capacity. [5][6]
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.
FAQ
What is GNOS-PV01 in glioblastoma research? [2]
GNOS-PV01 is a personalized DNA-based therapeutic cancer vaccine developed with Geneos Therapeutics for glioblastoma. It targets patient-specific neoantigens identified from tumor sequencing and was evaluated in a Phase 1 study involving nine adults. [2]
What did the Phase 1 glioblastoma study report? [2]
Most participants showed increased immune-cell activity after vaccination, except one patient receiving immunosuppressive steroids. The study also reported encouraging survival trends versus historical benchmarks, although the cohort was small. [2]
What is EVX-04 from Evaxion? [3]
EVX-04 is an off-the-shelf AML therapeutic vaccine candidate designed with Evaxion’s AI-Immunology™ platform. It targets endogenous retroviral antigens and is currently supported by preclinical data. [3]
Why is hantavirus vaccine development challenging? [1]
Researchers cited the rarity and geographic dispersion of hantavirus outbreaks as barriers to traditional efficacy studies. USAMRIID investigators are evaluating neutralizing antibody responses as a possible effectiveness marker. [1]
What did the Tdap pregnancy review conclude? [4]
The review concluded that maternal Tdap vaccination reduced infant pertussis risk and did not identify meaningful increases in major maternal or neonatal safety risks across reviewed studies. [4]
What is the Biovac Kilimanjaro project? [6]
The Kilimanjaro project is an Africa-based vaccine manufacturing initiative supported by IFC and financing partners. It aims to expand local vaccine production capacity and reduce reliance on imported vaccines. [6]
Entities / Keywords
USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases)
Hantavirus, Andes virus, Hantaan virus, Puumala virus
GNOS-PV01, glioblastoma, neoantigen vaccine
Washington University School of Medicine, Mass General Brigham, Geneos Therapeutics
Evaxion, EVX-04, AML, AI-Immunology™
Tdap vaccine, pertussis, CIDRAP Vaccine Integrity Project
Ab&B Bio-Tech, RSV vaccine, CHO-cell platform
IFC, Biovac, Kilimanjaro project, AIM2030
References